Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Novavax is a promising biotechnology company with a strong focus on developing novel vaccines to respond to both known and emerging diseases. With a rich pipeline of high-value assets and potential partnerships, the company has the potential for significant growth and value creation. While there are risks associated with competition and regulatory challenges, Novavax's technology and strong management make it a solid investment opportunity for those with a longer-term outlook.

Bears say

Novavax is facing stiff competition in the crowded market of COVID-19 vaccines, with only a 15% peak penetration projected for its flagship product Nuvaxovid. Even with potentially differentiated tolerability and a strong showing in the 65+ market, the risk of lower market share, combined with a steep decline in COVID-19 vaccine market predicted by experts, leads to a negative outlook for the company's financials, with R&D and SG&A expenses likely to remain high and limited potential for significant revenues from royalties.

Novavax (NVAX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Buy based on their latest research and market trends.

According to 6 analysts, Novavax (NVAX) has a Buy consensus rating as of Sep 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.